An experimental MS therapy given as a nasal spray has started dosing its final participant in a Phase 2a trial of people with ...

The European Commission has approved Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents a significant advanceme ...

Retrospective longitudinal data linked declining serum albumin and total protein—measured roughly two years pre-conversion—to subsequent SPMS onset compared with contemporaneous RRMS controls. Higher ...

Sanofi SNY announced that the European Commission has approved its Bruton's tyrosine kinase (BTK) inhibitor, Cenrifki ...

Sanofi’s Cenrifki (tolebrutinib) has been approved by the European Commission to treat secondary progressive multiple ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...